Announced
Completed
Synopsis
Bausch + Lomb, an optical brand, completed the acquisition of XIIDRA, a non-steroid eye drop, from Novartis, a pharmaceutical company, for $2.5bn. “We expect to quickly take a leading position in the growing prescription dry eye category with the XIIDRA acquisition and MIEBO launch and, importantly, help the millions of patients not currently receiving adequate treatment for dry eye disease,” Brent Saunders, Bausch + Lomb Chairman and CEO.
Principals
Show Details & Financials
Sort
Search a database of more than 250,000 verified dealmakers
Receive automated updates on global transactions
Follow the activity, relationships and transactions of top dealmakers
© COPYRIGHT 2024 MERGERLINKS LIMITED.
ALL RIGHTS RESERVED.
15 BONHILL STREET, LONDON, EC2A 4DN, UNITED KINGDOM.